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Abstract
Background and Aims Great efforts have been made to
predict disease behavior over time and the response to
treatment in Crohn’s disease (CD). Such understanding
could personalize therapy. Early introduction of more
aggressive therapies to patients at high risk and no intro-
duction of predictable refractory treatments could become
possible. We hence tested the inﬂuence of the NOD2 car-
rier status on treatment response.
Patients and Methods In 185 CD patients (age 45 ±
9.8 years, female n = 108, minimum disease duration
10 years), the three most common polymorphisms
(p.Arg702Trp, p.Gly908Arg, p.Leu1007fsX1008)o fNOD2
were tested by polymerase chain reaction and sequencing.
Detailed clinical and medical history were obtained with a
standardized questionnaire and by reviewing the medical
charts. Treatments introduced were chosen by physicians
blinded to genotype data.
Results The frequency of the NOD2 variant allele was
about one-third (67, 30.2%) of CD patients. NOD2 carriers
were more often treated with systemic and locally active
steroids and with an immunosuppressant (Azathioprine/
6-MP). NOD2 mutation carrier status was more often
associated with systemic steroid [8.9% vs. wild-type (WT)
1.2%, P = 0.0086] and local-steroid refractory (14.9% vs.
WT 3.5%; P = 0.001). The WT patients were signiﬁcantly
higher refractory to immunosuppressant (12.8% vs. NOD2
carriers, 0.5%, P = 0.03). Most WT patients were treated
with TNF-a antagonists and remission rates were signiﬁ-
cantly higher in this group after 1 year of treatment (84%
vs. NOD2 carriers, 33%, P = 0.07).
Conclusions The study presents ﬁrst hints for the NOD2
carrier status to be predictive for response to therapy. A
higher percentage of CD patients with NOD2 mutation
carrier status was steroid refractory but could be treated
well with immunosuppressants. The WT status showed a
higher response to steroids and remission rates within
1 year of anti-TNF-a therapy. On the way to personalized
medicine, this approach should be further investigated in
larger studies.
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Crohn’s disease (CD) is a chronic inﬂammatory disorder of
the gastrointestinal tract. It is a multifactorial, polygenic
disease with genetic heterogeneity. In addition to genetic
predisposition, various host (e.g., epithelial, immune, and
nonimmune) and environmental factors play a major role in
the pathogenesis of CD [1, 2]. Guidelines recommend that
most patients with active disease should be treated initially
with corticosteroids [3, 4]. Although this approach is usu-
ally effective for control of symptoms, many patients
become refractory to, or dependent on, these drugs [5, 6].
For this reason, a treatment with corticosteroid-sparing
drugs, such as azathioprine, mercaptopurine, or metho-
trexate, should be initiated [7–9]. Recent published data
underline the concept of an early combined immunosup-
pression in CD, the so-called ‘‘top-down’’ strategy [10].
A combined immunosuppressive therapy with anti-
metabolites/methotrexate and TNF-a antagonists is asso-
ciated with a higher risk of opportunistic infections and
hepatosplenic T cell lymphoma [11]. Therefore, great
efforts have been made to predict disease behavior over
time and the response to treatment in CD. Early introduc-
tion of more aggressive therapies to patients at high risk of
disabling disease, and no introduction of predictable
refractory treatments to reduce side effects of therapies,
could become possible [12]. Attempts have been made to
deﬁne clinical subgroups on the basis of age at onset,
disease location, extent (diffuse or localized), and behavior
(primary inﬂammatory, ﬁstulizing, or ﬁbrostenotic dis-
ease). Mucosal TNF-a transcripts in steroid-refractory CD
patients receiving immunosuppressive therapy may have
predictive values [13].
Crohn’s disease has a strong genetic component, with a
lifetime risk of 10–20% to develop CD in the presence of
an affected ﬁrst-degree relative, thus deﬁning subgroups
based on genetic mutations might be a helpful marker [14,
15]. To date, genome-wide meta-analysis has identiﬁed at
least 71 loci that confer susceptibility to CD [16]; the ﬁrst,
and most consistently replicated, critical mutations were
found in the CARD15/NOD2 gene on chromosome 16
(IBD1) [17]. The physiological role of the NOD2 protein
remains under detailed examination. Variant NOD2 alleles
are associated with reduced (alpha)-defensin release from
Paneth cells in response to bacteria [18]. Of particular
importance is the C-terminus leucine-rich repeat domain,
reportedly the major structural motif that functions as a
pattern-recognition receptor for the microbial component
muramyl dipeptide [19].
Two single-nucleotide polymorphisms of NOD2
(p.Arg702Trp and p.Gly908Arg) and a frame-shift muta-
tion (p.Leu1007fsX1008) were shown by independent
groups to be associated with susceptibility to CD [20–22].
The presence of 1 variant allele increases the risk of
developing CD from 1.5- to 4.3-fold; the presence of 2
copies increases the risk to 20- to 40-fold [23–25]. CD
patients with NOD2 mutations exhibit early onset of the
disease, mainly ileal involvement and increased risk of
surgical intervention after developing complications such
as strictures, ﬁstulas and stenosis [14, 17, 26]. NOD2
mutation carrier status does currently not allow the pre-
dicting of disease progression and the need of immuno-
suppressive therapies such as steroids, azathioprine or
biologicals (i.e. TNF-a antagonists).
Based on these observations, we aimed to test a possible
inﬂuence of the NOD2 carrier status on response to stan-
dard medical treatments. Such understanding could per-
sonalize therapy.
Patients and Methods
Study Population and Disease Phenotype
Written, informed consent was obtained from all patients
prior to the study. The study was approved by the Ethics
committee of the Ulm University and adhered to the ethical
principles for medical research involving human subjects
of the Helsinki Declaration (http://www.wma.net/e/policy/
b3.htm). For the diagnosis of CD, established diagnostic
guidelines including endoscopic, radiological, and histo-
pathological criteria were used [27]. Patients with CD were
assessed according to the Montreal classiﬁcation based on
age at diagnosis (A), location (L), and behavior (B) of the
disease. Patients with colonic inﬂammatory bowel disease
unclassiﬁed (IBDU) were excluded from the study. Phe-
notypic characteristics included demographic data and
clinical parameters (behavior and anatomic location of
IBD, disease-related complications, previous surgery or
immunosuppressive therapy) which were recorded by
investigation of patient charts and a detailed questionnaire
including an interview at the time of enrolment. All phe-
notypic data were collected blind to the results of the
genotypic data.
DNA Extraction and Genotyping of the NOD2 Variants
Blood samples were taken from all study participants, and
genomic DNA was isolated from peripheral blood leuko-
cytes using the DNA blood mini kit from Qiagen (Hilden,
Germany) according to the manufacturer’s guidelines.
DNA was ampliﬁed by PCR with primer pairs ﬂanking the
p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008 vari-
ants as described [28]. After puriﬁcation, PCR products
were analyzed with the ABI PRISM Dye Terminator Cycle
Sequencing KIT (Applied Biosystems, Darmstadt,
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123Germany) on an ABI 373A DNA-sequencer using the same
primers applied for ampliﬁcation.
Deﬁnitions of Response to Therapy
All patients were treated according to the German clinical
practice guidelines on the diagnosis and treatment of CD
[27] blinded to the genotype data. Patients received
budesonide (9 mg/day), prednisolone (2 mg/kg up to
60 mg), immunomodulators (2.5 mg/kg for AZA and
1–1.5 mg/kg for 6-MP), inﬂiximab (5 mg/kg at weeks 0, 2,
6 and every 8 weeks) or adalimumab (80 mg starting dose
followed by 40 mg every second week). When patients
were treated with steroids, remission was deﬁned by a
decrease of the CDAI score to 150 or less. Patients who
responded to prednisolone but relapsed upon steroid
withdrawal were deﬁned as steroid-dependent. Patients
who did not respond to steroids, deﬁned by decrease of the
CDAI score of at least 70 within the ﬁrst 4 weeks, were
deﬁned as steroid-refractory [27]. When immunomodula-
tors (AZA/6-MP) were given, clinical remission was
deﬁned by a decrease of the CDAI score to 150 or less after
steroid withdrawal for more than 3 months. When TNF-a
antagonists (inﬂiximab/adalimumab) were used, remission
was deﬁned as a decrease of the CDAI score to 150 or less
after 2–3 infusions (inﬂiximab, weeks 3–7) or after 3
injections (adalimumab, week 6).
Statistical Analyses
All data given in the text and ﬁgures are expressed as mean
values ± SEM. The data were analyzed using non-para-
metric two-tailed Mann–Whitney U test with P B 0.05
considered as an indicator of signiﬁcance. In addition, a
multivariate assessment of the relationship between the
independentvariables‘‘group[wild-type(WT)vs.NOD2],’’
‘‘localization (ileus, colon, etc.),’’ ‘‘stricture (yes vs. no),’’
‘‘ﬁstula (yes vs. no),’’ ‘‘surgery (yes vs. no)’’ and the
dependent outcome variable ‘‘therapy response to steroids
(yesvs.no)’’wascarriedout.Duetothebinarycharacteristic
ofthedependentvariable‘‘therapyresponse,’’amultivariate
logistic regression model has been chosen as statistical
method for analyzing the data.
Results
Demographic Characteristics of the Study Population
One hundred and eighty-ﬁve patients were included in our
retro-perspective study. NOD2 carrier status was found in
77 patients including 1 homozygous NOD2 carrier. The
demographic characteristics and disease location according
to the Montreal classiﬁcation are depicted in Table 1. More
patients with NOD2 variants had disease location at the
ileal site; signiﬁcantly more patients with NOD2 carrier
Table 1 Demographic characteristics of the study population
NOD2
-/- NOD2
?/- NOD2
?/? Signiﬁcance P value
Male n (%) 41 (53%) 35 (45%) 1 (1.3%) 0.634
Median age at diagnosis (year) 30.1 (14–59) 26.4 (15–48) 18 0.712
Disease location (n and %) (Vienna)
Ileal disease: L1 26/118 (22.1%) 21/68 (30.9%) 0.1076
Colonic disease: L2 10 (8.2%) 3 (4.1%) 0.09
Ileocolonic disease: L3 59 (50.8%) 33 (48.8%) 1 0.7966
Upper gastrointestinal involvement 15 (13.1%) 2 (3.1%) \0.05
Anal involvement
a 24 (21.1%) 10 (14%) 1 0.134
Disease behavior (n and %) Vienna
Inﬂammatory (B1) 48 (41%) 34 (50.5%) 1 0.356
Stricturing (B2) 16 (14%) 19 (28.2%) 1 0.08
Penetrating (B3) 53 (45%) 20 (29%) 1 \0.05
Need for IBD surgery 52 (44%) 49 (72%) 1 \0.05
History of smoking 63 (53%) 31 (45%) Not signiﬁcant
Extraintestinal manifestations 39 (33%) 24 (35%) Not signiﬁcant
p.Arg702Trp 31
p.Gly908Arg 34 1
p.Leu1007fsX1008 18
a (L1) ? (L3) ? (L4 - patients with ileal involvement)
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123status developed stricturing and/or penetrating disease
behavior as compared to NOD2 WT patients conﬁrming
previous reports (Table 1).
Ninety-four patients were initially treated with budeso-
nide including 42 NOD2 carriers, 140 patients including
62 NOD2 carriers were treated with prednisolone,
68 patients were treated with immunosuppressants(AZA/
6-MP),including33NOD2carriers,and25patientsreceived
TNF-aantagonists(inﬂiximaboradalimumab,respectively)
(Table 2).
More NOD2 Carriers are Refractory to Treatment
with Budesonide
First, we determined the response to budesonide. Seventy-
one percent of NOD2 WT patients responded to the treat-
ment with budesonide, 21% were budesonide-dependent
and 8% were refractory to budesonide. Budenoside treat-
ment of NOD2 WT patients was more effective in patients
with ileal-cecal disease location. When NOD2 carriers
were analyzed, 33% of NOD2 carriers responded to
budesonide, 19% were steroid-dependent and 48% were
refractory to treatment with budesonide. Budesonide-
treated patients with NOD2 variants were signiﬁcantly
impaired in response to budesonide (Fig. 1). Together, this
data indicated that patients with NOD2 WT status show
better response rates to budesonide as compared to patients
with NOD2 variants.
Impaired Response to Prednisolone in CD Patients
with NOD2 Carrier Status
Next, we determined the response to prednisolone in our
study collective. Fifty-seven percent of patients with NOD2
WT status were sensitive to the treatments with predniso-
lone, 39% were steroid-dependent, and 2% were refractory
to prednisolone treatment. When NOD2 carriers were
analyzed, 46% of NOD2 carriers were sensitive to pred-
nisolone, 35% were steroid-dependent, and 17% were
refractory to treatment with prednisolone. Again, signiﬁ-
cantly more patients with NOD2 variants were refractory to
prednisolone as compared to patients with NOD2 WT
status, but this difference was not as pronounced as with
budesonide (Fig. 1). Because more patients with NOD2
variants had disease location at the ileal site and developed
more likely stricturing and/or penetrating disease behavior,
we tested in a multivariate logistic regression model if the
independent variables localization (ileal site), stricturing or
internal ﬁstulizing disease behavior and surgery inﬂuence
the therapy success of the treatment with steroids. The
success of treatment with steroids did not depend on dis-
ease location, the development of stricturing and/or pene-
trating disease behavior and not on surgery. The success of
treatment with prednisolone depended in our model and
patient collective only on the NOD2 carrier status
(Table 3).
Response of NOD2 Carriers to Immunomodulators
(AZA/6-MP)
Because the percentage of patient refractory to the treat-
ment with prednisolone was signiﬁcantly increased among
the patients with NOD2 variants as compared to patients
with NOD2 WT status, we next analyzed the response of
patients with NOD2 variants to immunomodulators (AZA/
6-MP). Sixty-ﬁve percent of patients with NOD2 WT status
went into remission under treatment with AZA/6-MP,
whereas 34% of patients with NOD2 WT status were
refractory to treatment with AZA/6-MP. Eighty-eight per-
cent of patients with NOD2 variants went into remission
under treatment with AZA/6-MP, and 12% of patients with
NOD2 variants were refractory to treatment with AZA/
6-MP. The percentage of patients with NOD2 variants in
remission under treatment with AZA/6-MP was signiﬁ-
cantly increased as compared to patients with NOD2 WT
status (Fig. 1). In contrast, signiﬁcantly more patients with
NOD2 WT status were refractory to treatment with AZA/
6-MP as compared to patients with NOD2 variants.
Table 2 Medication of the study population including 67 patients with NOD2 variants
Medication Study collective
a WT NOD2 status
b NOD2 carrier
c
Budesonide 50.8% (94/185) 44.1% (52/118) 62% (42/67)
Prednisolone 75.7% (140/185) 66.1% (78/118) 92.5% (62/67)
Immunomodulators 36.7% (68/185) 39.7% (35/118) 49.2% (33/67)
Anti-TNF-a 13.5% (25/185) 15.3% (18/118) 10.4% (7/67)
a Percentage of patients of the total study collective receiving the indicated medication. The numbers in parentheses indicate the total numbers of
patients within the study collective of 185 patients treated by the indicated medication
b Percentage of patients with the WT NOD2 status treated by the indicated medication. The numbers in parentheses indicate the total numbers of
118 patients with WT NOD2 status receiving the indicated medication
c Percentage of patients with NOD2 variants receiving the indicated medication. The numbers in parentheses indicate the total numbers of 67
patients with NOD2 variants treated by the indicated medication
882 Dig Dis Sci (2012) 57:879–886
123Response of NOD2 Carriers to Treatment with TNF-a
Antibodies (Inﬂiximab/Adalimumab)
We next analyzed the response of the patients to the TNF-a
antagonists inﬂiximab or adalimumab. Eighty-nine percent
of patients with NOD2 WT status went into remission
under treatment with TNF-a antagonists. Eleven percent of
patients with NOD2 WT status were refractory to treatment
with TNF-a antagonists. Fifty-seven percent of patients
with NOD2 variants were sensitive to TNF-a antagonists,
and 43% of patients with NOD2 variants were refractory to
TNF-a antagonists (Fig. 1).
All together, our results demonstrate that CD patients
with NOD2 WT status differ in response to standards of
medication as compared to NOD2 carriers.
Discussion
Treatment algorithms and the drug history in CD in
dependence on the NOD2 mutation carrier status have not
yet been investigated. We have shown that patients with
CD and NOD2 carrier status were more refractory for
steroids but could be treated well with immunosuppres-
sives. The patients with WT NOD2 status, who were ste-
roid-dependent, showed a signiﬁcantly lower response to
treatment with immunomodulators (AZA/6-MP).
In our patients, more CD patients with NOD2 variants
were refractory to treatment with budesonide and/or pred-
nisolone. In a multivariate logistic regression model,
treatment success with prednisolone was independent of
disease localization (ileal site), stricturing or internal
p=0.0086
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Fig. 1 a The percentage of patients with NOD2 WT status responding
to treatment with budesonide is increased as compared to patients with
NOD2 variants. The percentage of patients refractory to budesonide
treatment is presented. b The percentage of patients with NOD2 carrier
status refractory to prednisolone treatment is increased. In the non-
parametric two-tailed Mann–Whitney Utest, P B 0.05 was considered
statistically signiﬁcant; WT, NOD2 wild-type status; NOD2, patients
with NOD2 variants. c The percentage of patients with NOD2 carrier
status in remission under treatment with immunomodulators (AZA/
6-MP) is increased as compared to patients with NOD2 wild-type
status. The percentage of patient in remission under treatment with
AZA/6-MP with NOD2 carrier status was compared with WT NOD2
patients. d Patients with NOD2 wild-type status respond to treatment
with TNF-a antagonists. Black area indicates the percentage of
patients in remission under treatment with TNF-a antagonist, and the
white area indicates the percentage of patients responding to treatment
with TNF-a anatgonist. Numbers within the area indicate the numbers
of patients within the total numbers of patients per indicated group;
numbers on top of the bars indicated the percentage of patients in the
respective group. A non-parametric two-tailed Mann–Whitney U test
was used; P B 0.05 was considered as an indicator of signiﬁcance;
WT, NOD2 wild-type status; NOD2, patients with NOD2 variants
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123ﬁstulizing disease behavior, and the need for surgery.
Another study could not ﬁnd an association of NOD2
carrier status and response to steroids [29]. In contrast to
the study of Weiss et al., median age of disease is
[18 years in our study cohort. Carrying out the analysis of
treatment responses in dependence of NOD2 variants may
differ signiﬁcantly between patient cohorts with pediatric
and adult CD patients.
Associations between polymorphism in the TNF-a gene,
but not in the multidrug resistance gene 1 (MDR-1), and
response to treatment with steroids has been described in an
Italian pediatric IBD cohort [30]. High expression of glu-
cocorticoid receptors by mononuclear cells in the peripheral
blood of CD patients may predict the response to treatment
with steroids [31]. Data of glucocorticoid receptor expres-
sion of CD patients with or without NOD2 mutation carrier
status are still missing. In patients receiving TNF-a antago-
nists gene expression proﬁling and IL-23R variants may
predict treatment response to TNF-a antagonists [32, 33]. It
might be possible that patients with a reduced glucorticoid
receptor expression could have beneﬁted from early com-
bination therapy with immunosuppressants [12].
In our study, CD patients with NOD2 WT status
responded to steroids. The percentage of patients with
NOD2 WT status refractory to budesonide or prednisolone
was decreased as compared to patients with NOD2 carrier
status.
More patients with NOD2 carrier status were treated
with AZA/6-MP, and the percentage of patients going into
remission under treatment with AZA/6-MP was increased
as compared to patients with NOD2 WT status. AZA/6-MP
metabolites and TPMT activity were not detected on a
routine basis in our study [34, 35]. Because most patients
received remission under treatment with AZA/6-MP, the
discrepancy between patients with NOD2 WT status and
patients with NOD2 variants may be associated with
genetic and biochemical factors that need to be deﬁned in
future studies.
The AZA/6-MP refractory patients with NOD2 WT
showed response to TNF-a antagonists. Several studies
have investigated the inﬂuence of NOD2 polymorphism on
response to TNF-a antagonists. NOD2 polymorphism is not
predictive for the outcome of treatment with inﬂiximab
[36, 37]. We included in our study patients treated with
inﬁximab and adalimumab which may explain differences
to previous studies.
NOD2 carriers are characterized by early onset of CD
associated with strictures and penetrating disease behavior
and increased need for surgery as previously reported [38–
40]. In our patients, NOD2 carriers are characterized by
early onset of disease, but increased need for surgery could
not be conﬁrmed.
Disease phenotype and location are considered to pre-
dict disabling disease. Young age, smoking habits, perianal
lesions and severe ulcerations are clinical predictors of risk
for progressive disease [15, 41]. All treatment regimens in
our study were chosen by an algorithmic approach based
on national guidelines [27]. Selection of medication
depended on the interpretation of the clinical data by the
individual physician blinded to the NOD2 genotype status.
Interpretation of the results of our study is limited by the
facts that analysis of remission rates depending on treat-
ment regimen was carried out in a retrospective manner,
and not in a prospective controlled clinical trial at a single
IBD study center only, and not in a multicentre approach.
In our study with a limited sample size, a replication cohort
is missing. Carrying out genome-wide association studies
(GWAS) could be particularly interesting to identify
additional variants associated with disease behavior and
response to treatment with standard medication.
The task to choose the right medication for an individual
IBD patient will likely become more complex in future.
Although the prediction of treatment response by pheno-
type, genotype and serological parameters is still in its
infancy, the individual choice of the treatment regimen
may help to maximize efﬁcacy, minimize delays to effec-
tive treatment, and improve safety and tolerability.
In conclusion, our data show that CD patients without
NOD2 mutations suffering from a steroid-dependent or
refractory course have signiﬁcantly less chance to reach
steroid-free remission by a treatment with immunosup-
pressive agents as compared to CD patients with NOD2
mutations, which was independent disease localization
(ileal site), stricturing or internal ﬁstulizing disease
behavior, and the need for surgery. Otherwise, these NOD2
WT status patients were very sensitive to anti-TNF-a
antibodies and all patients reached steroid-free remission.
Although this group of patients was small in our study, our
results give a ﬁrst hint that a top-down therapy strategy
could be effective especially in these patients. Further
studies are needed to prove this concept. This could be an
important step toward a personalized therapy in CD
patients.
Table 3 Effects of the independent variables localization (ileal site),
stricturing or internal ﬁstulizing disease behavior and surgery on
therapy success with systemic steroids in a multivariate logistic
regression model
P value
Localization (ilelal site L1 ? L3) 0.4682
Stricturing (B2) 0.1015
Internal ﬁstulizing (B3) 0.8845
Surgery 0.8992
In the multivariate logistic regression model, a P value \0.05 was
considered as statistically signiﬁcant
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